Dynacure Announces Approval of Clinical…
Strasbourg (France)April 30, 2019Company expects to initiate Phase 1 / 2 study ‘Unite-CNM’ in 2H2019 Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Clinical Trial Application (CTA) for DYN101, an investigational antisense medicine designed to modu
READ MOREDynacure receives Research Grant from…
Strasbourg (France)April 25, 2019Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, today announced the award of a research grant of 450 000 euros from Programme d’Investissements d’Avenir (PIA3) Grand Est operated by Bpifrance. The research grant will advance and expand the development of Dynacure’s lead drug program (Dyn-101), an antisense oligonucleotide des
READ MOREDynacure promotes Belinda Cowling (PhD)…
StrasbourgFebruary 12, 2019Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, today announced the promotion of Belinda Cowling (PhD) to Chief Scientific Officer and Leen Thielemans (PhD) to Chief Development Officer. Belinda Cowling’s (PhD) research at the IGBMC (Strasbourg) led to the creation of Dynacure in 2016, of which she is cofounder and was scientific
READ MOREDynacure appoints Georges Gemayel (PhD)…
StrasbourgOctober 9, 2018Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, today announced the appointment of Georges Gemayel (PhD) as chairman of its Board of Directors. "I am very pleased to welcome Georges to Dynacure’s Board of Directors during this exciting stage in our company's growth. His extensive experience will strengthen the team’s mission to
READ MOREInnovative modelling approach by Dynacure/ISMS…
StrasbourgAugust 31, 2018Dynacure’s recent publication in ‘Neuromuscular Disorders’, co-authored with Dr Laurent Servais, Dr Jim Dowling and Dr Valérie Biancalana: ‘An integrated modelling methodology for estimating the prevalence of centronuclear myopathy’ This innovative modelling approach by Dynacure/ISMS resulted in the 1st peer reviewed study on quantification of the CNM patient population with a d
READ MOREDynacure names Chris Freitag (MD)…
Strasbourge (France)July 10, 2018Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today the expansion of its leadership team with the appointment of Chris Freitag (MD) as Chief Medical Officer. He will be responsible for the company’s medical strategy, clinical operations and expand Dynacure’s network with medical and academic organizations. “I’m e
READ MOREDynacure secures €47 million financing…
Strasbourge (France)July 6, 2018Financing will support clinical development of lead antisense oligonucleotide candidate for centronuclear myopathy (CNM), and additional preclinical research programs forotherorphan disorders Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today the completion of a €47 million financing round (~US$55 million) to advance
READ MOREBelinda Cowling (PhD) joins Dynacure…
Strasbourg (France)April 30, 2018Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today that Belinda Cowling (PhD) has joined the management team as Head of Research. Dynacure’s first drug discovery program focuses on centronuclear myopathies (CNM), a rare debilitating disease affecting children and young adults, through the use of an antisense oligonu
READ MOREIonis licenses novel antisense drug…
Carlsbad, Calif. and Strasbourg, FranceNovember 9, 2017Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear myopathy (CNM), for which Ionis earned a $5 million license fee in the form of Dynacure equity. Dynacure will now assume all development and commercialization responsibilities for the pro
READ MOREDynacure joins ongoing Natural History…
Strasbourg (France)September 26, 2017Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathy (CNM), a debilitating rare disease affecting children and young adults. Dynacure’s development program is using an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals. Dynac
READ MOREDynacure appoints its Management Team…
Strasbourg (France)March 9, 2017Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a debilitating rare disease affecting children and young adults. Dynacure’s development program is using an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals. The
READ MOREKurma Partners and Idinvest Partners…
ParisOctober 24, 2016Kurma announced on Monday the 24th of October 2016, that they have entered into a collaboration agreement with Conectus and Ionis Pharmaceutical to launch Dynacure, a Strasbourg-based biotech specializing in the treatment of rare neuromuscular disorders. Dynacure is a spin-off from the IGBMC (Institute of Genetic and Molecular and Cellular Biology – Unistra/INSERM/CNRS) of Strasbourg. “The
READ MORE